Abstract 529P
Background
Ramucirumab (RAM) plus docetaxel (DOC) combination therapy is one of the standard treatment options for second-line in patients with advanced NSCLC. Previous studies reported that history of pre-administration of immune checkpoint inhibitors was related to good outcomes with RAM plus DOC. However, the clinical significance of RAM plus DOC after combined immunotherapy is little known. Therefore, we evaluated RAM plus DOC after combined chemoimmunotherapy and attempted to identify predictors for their outcomes.
Methods
This multicenter prospective study aimed to investigate the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy. The primary endpoint was progression-free survival (PFS). The secondary endpoints are objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of adverse events (AEs). Serum cytokines at the start of treatment were measured as an exploratory investigation.
Results
A total of 44 patients were enrolled, at 10 Japanese institutions from November 2019 and March 2021. The median PFS was 6.3 months (95% confidence interval [CI]: 4.2–8.8), and the median OS was 22.6 months (95% CI: 13.9–NE). The ORR and DCR were 36.4% (95% CI: 22.4–52.2) and 72.7% (95% CI: 57.2–85.0). High VEGF-D groups had significantly shortened PFS and OS. The combination of high VEGF-A and low VEGF-D had a longer PFS than other groups.
Conclusions
The primary endpoint was met; RAM plus DOC after combined chemoimmunotherapy is an effective and relatively feasible second-line treatment in patients with advanced NSCLC in the real-world setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Yamada, K. Takayama: Financial Interests, Personal, Invited Speaker: Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract